Literature DB >> 10090571

Identification of renal podocytes in multiple species: higher vertebrates are vimentin positive/lower vertebrates are desmin positive.

E Yaoita1, W W Franke, T Yamamoto, K Kawasaki, I Kihara.   

Abstract

We sought to characterize podocytes in the kidneys of numerous species from amphibians to mammals because of the pivotal function of these cells in renal diseases. For this purpose, intermediate filament (IF) proteins of podocytes were examined by immunofluorescence microscopy using antibodies against vimentin, cytokeratins, and desmin. These staining patterns were then compared to those of parietal cells of Bowman's capsule and tubular cells of the first portion of the proximal tubule from the same sources. As a result, podocytes from mammals (rat, rabbit, dog, cow, and human) and birds (chicken) showed intense vimentin staining without exception, but rarely staining for cytokeratins or desmin. Parietal cells from all these animals were highly heterogeneous with respect to cytokeratin or vimentin staining. Of the tubular cells, only those from humans and chickens were reactive and then only with anti-cytokeratin antibodies. In the reptiles (Chrysemys scripta elegans, Chinemys reeveri, Elaphe quadrivirgata, and Anolis carolinensis), podocytes and other epithelial cells were positive for cytokeratins. Vimentin staining differed among the species, but was not characteristic for podocytes. Anti-desmin antibody reacted strongly only with podocytes from Anolis. In amphibians (Rana catesbeiana and Xenopus laevis), anti-desmin antibody stained podocytes more intensely than any other cell. Cytokeratin and vimentin staining did not differentiate podocytes from the other cell types. These findings indicate that podocytes are characterized by intense vimentin staining in the higher vertebrates and by desmin staining in the lower vertebrates denoting potentially distinctive physiological functions of IF proteins in podocytes from each of these groups.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10090571     DOI: 10.1007/s004180050340

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  6 in total

1.  Rituximab treatment prevents the early development of proteinuria following pig-to-baboon xeno-kidney transplantation.

Authors:  Masayuki Tasaki; Akira Shimizu; Isabel Hanekamp; Radbeh Torabi; Vincenzo Villani; Kazuhiko Yamada
Journal:  J Am Soc Nephrol       Date:  2014-01-23       Impact factor: 10.121

2.  Tissue specific characterisation of Lim-kinase 1 expression during mouse embryogenesis.

Authors:  Nils O Lindström; Carlos Neves; Rebecca McIntosh; Zosia Miedzybrodzka; Neil Vargesson; J Martin Collinson
Journal:  Gene Expr Patterns       Date:  2010-12-16       Impact factor: 1.224

3.  Upregulated expression of integrin α1 in mesangial cells and integrin α3 and vimentin in podocytes of Col4a3-null (Alport) mice.

Authors:  Brooke M Steenhard; Roberto Vanacore; David Friedman; Adrian Zelenchuk; Larysa Stroganova; Kathryn Isom; Patricia L St John; Billy G Hudson; Dale R Abrahamson
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

Review 4.  Podocytes … What's Under Yours? (Podocytes and Foot Processes and How They Change in Nephropathy).

Authors:  Chris R Neal
Journal:  Front Endocrinol (Lausanne)       Date:  2015-02-23       Impact factor: 5.555

5.  Adiponectin protects obesity-related glomerulopathy by inhibiting ROS/NF-κB/NLRP3 inflammation pathway.

Authors:  Xiaohong Xu; Xiaolin Huang; Liexiang Zhang; Xiaoli Huang; Zihan Qin; Fei Hua
Journal:  BMC Nephrol       Date:  2021-06-10       Impact factor: 2.388

6.  Induction of protein citrullination and auto-antibodies production in murine exposed to nickel nanomaterials.

Authors:  Bashir M Mohamed; Noreen T Boyle; Anja Schinwald; Bruno Murer; Ronan Ward; Omar K Mahfoud; Tatsiana Rakovich; Kieran Crosbie-Staunton; Steven G Gray; Ken Donaldson; Yuri Volkov; Adriele Prina-Mello
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.